About Intus Biosciences
Intus Biosciences is a private company based in Farmington, Connecticut. It has reported $10,116,492 raised in ten offerings on Form D since January 2016. Its chief executive is Paul Denslow.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| May 15, 2025 | May 27, 2025 | $1,089,996of $3.0M target | 8 | $136K | EquityRule 506(b) | Form D ↗ |
| Jun 25, 2024 | Jul 16, 2024 | $2,000,000fully sold | 25 | $80,000 | Equity, DebtRule 506(b) | Form D ↗ |
| Nov 7, 2022 | Nov 16, 2022 | $1,050,003of $3.4M target | 1 | $1.0M | Equity, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 27, 2022 | Jul 7, 2022 | $800,000of $1.5M target | 1 | $800K | DebtRule 506(b) | Form D ↗ |
| Jan 22, 2022 | Feb 3, 2022 | $250,000fully sold | 4 | $62,500 | DebtRule 506(b) | Form D ↗ |
| Dec 23, 2020 | Jan 8, 2021 | $330,000of $1.0M target | 5 | $66,000 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 23, 2019 | Aug 12, 2019amended May 27, 2020 | $2,214,434fully sold | 16 | $138K | Equity, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 15, 2017 | Dec 28, 2017 | $1,842,059of $1.9M target | 10 | $184K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| May 13, 2016 | May 31, 2016 | $500,000fully sold | 1 | $500K | Equity, Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 7, 2016 | Jan 25, 2016 | $40,000of $500K target | 1 | $40,000 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, ten offerings | $10,116,492 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Intus Biosciences's Form D filed May 27, 2025.
Earlier filings also listed Thomas Jarvie (executive officer and director, last listed Nov 2022), Matt Watson (director, last listed Nov 2022), William McKenzie (director, last listed Jul 2022), H. Mark Lunenburg (director, last listed Jul 2022), David Wurzer (director, last listed Jul 2022) and Patrick O'Neill (director, last listed Jan 2021).